文献速递多重用药老年慢病共病管理

中国老年人可操作药物基因组生物标志物的使用及可能的处方调整

Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.
PubMed 文献 · J Am Geriatr Soc · 2025-09-29

该回顾性横断面分析利用2015-2017年中国医疗保险研究会数据,涵盖3,309,025名≥65岁患者和74,415,484张处方,评估CPIC A级药物处方率及基因导向剂量调整的潜在影响。结果显示43.4%老年人曾使用至少一种A级药物,36.5%的暴露需基因导向剂量调整,CYP2C19和SLCO1B1为最高优先级基因-药物对。

要点

  • 43.4%中国老年人使用至少一种CPIC A级药物,阿托伐他汀、奥美拉唑、氯吡格雷最常见。
  • 36.5%的药物暴露需基因导向剂量调整,氯吡格雷(CYP2C19)和他汀(SLCO1B1)优先级最高。
  • 建议将药物基因组检测整合入老年医疗,优先检测CYP2C19和SLCO1B1并制定区域特异性指南。

核心结论

  • CPIC A级药物基因组生物标志物在中国老年人中普遍存在,超过40%暴露于可操作基因-药物对,36.5%需剂量调整。

研究设计与样本

  • 回顾性横断面分析,使用2015-2017年中国医疗保险研究会(CHIRA)理赔数据,纳入3,309,025名≥65岁患者和74,415,484张处方。

主要发现

  • 43.4%(433.8/1000)老年人曾使用至少一种CPIC A级药物,阿托伐他汀(131.1/1000)、奥美拉唑(124.3/1000)、氯吡格雷(75.7/1000)最常见。
  • 36.5%(365.3/1000)的药物暴露需基因导向剂量调整。
  • 最高优先级基因-药物对为氯吡格雷(CYP2C19,259.6/1000)和他汀类(SLCO1B1,221.8/1000)。

关键数值与推荐

  • CPIC A级证据药物共53种。
  • 可操作表型驱动剂量调整率基于PharmGKB及已发表的人群特异性基因频率估算。

临床怎么用

  • 将药物基因组检测整合入老年医疗,优先检测CYP2C19和SLCO1B1以降低多重用药风险。
  • 政策制定者和临床医生应考虑针对性实施策略以优化老年人群处方安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacogenetic testing offers a pathway to safer prescribing and improved outcomes in older adults, who face heightened risks of adverse drug reactions due to polypharmacy and age-related metabolic changes. This study evaluates the prevalence of actionable pharmacogenetic biomarker use and estimates the potential impact of genotype-guided dosing in Chinese older adults. METHODS: This retrospective cross-sectional analysis utilized 2015-2017 claims data from the China Health Insurance Research Association (CHIRA), encompassing 3,309,025 older patients (≥ 65 years) and 74,415,484 prescriptions. Drugs with Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A evidence for actionable pharmacogenetic variants (n = 53) were identified. Key measures included the prescribing prevalence of Level A drugs and projected rates of actionable phenotype-driven dosing changes, calculated using population-specific genotype frequencies from PharmGKB and published sources. RESULTS: Among older adults, 43.4% (433.8 per 1000) were prescribed ≥ 1 CPIC Level A drug. Atorvastatin (131.1 per 1000), omeprazole (124.3 per 1000), and clopidogrel (75.7 per 1000) were the most common. Over one-third (36.5%; 365.3 per 1000) of exposures required genotype-guided dose adjustments, with clopidogrel (CYP2C19) and statins (SLCO1B1) representing the highest-priority gene-drug interactions (259.6 and 221.8 per 1000, respectively). CONCLUSIONS: CPIC Level A pharmacogenetic biomarkers are prevalent in Chinese older adults, with over 40% exposed to actionable gene-drug pairs and 36.5% requiring dose adjustments. These findings highlight the clinical imperative to integrate pharmacogenetic testing into geriatric care, prioritize CYP2C19 and SLCO1B1 testing, and develop region-specific guidelines to mitigate polypharmacy risks. Policymakers and clinicians should consider targeted implementation strategies to optimize prescribing safety and efficacy in aging populations.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Zhao Z, Zhao Y, Hu X, et al. Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People. J Am Geriatr Soc. 2025. PMID: 41017291. doi:10.1111/jgs.70126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。